483 Round-Up: FDA Hits Four Facilities for Testing, Cleaning, Procedural Issues

Drug GMP Report
A A
The FDA issued a flurry of Form 483s to drugmakers in the United States, Japan and India for issues ranging from inadequate record-keeping to cleanliness issues.

To View This Article:

Login

Subscribe To Drug GMP Report